ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

VXCO-102

A development code.

Its studies are mostly in Epstein-Barr Virus Infections, led by Eli Lilly.

Furthest: phase 1, since Apr 22, 20261 company-led study, 1 open or runningNext primary completion: Feb 29, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly11 open or runningphase 1since Apr 22, 2026Apr 22, 2026Feb 29, 2028phase 1 · NCT07557602

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 22, 2026First study: phase 1 study in Epstein-Barr Virus InfectionsFirst studyNCT07557602 · 82 planned · Australia
  2. Oct 26, 2026Primary completion moved from 2027-08-31 to 2028-02-29Date moved laterphase 1 · +6 months · NCT07557602

Ahead

  1. Feb 29, 2028Primary completion: phase 1 study in Epstein-Barr Virus InfectionsNCT07557602

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07557602Epstein-Barr Virus Infections · Australia1RecruitingFeb 29, 202882

How it is read

Names in the registry

  • “VXCO-102”, 1 entry

Codes read as this program: VXCO102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.